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The chromatin remodeler CHD5 is expressed in neu-
ral tissue and is frequently deleted in aggressive
neuroblastoma. Very little is knownabout the function
of CHD5 in the nervous system or its mechanism of
action. Here we report that depletion of Chd5 in the
developing neocortex blocks neuronal differentiation
and leads to an accumulation of undifferentiated
progenitors. CHD5 binds a large cohort of genes
and is required for facilitating the activation of
neuronal genes. It also binds a cohort of Poly-
comb targets and is required for the maintenance
of H3K27me3 on these genes. Interestingly, the chro-
modomains of CHD5directly bindH3K27me3 and are
required for neuronal differentiation. In the absence
of CHD5, a subgroup of Polycomb-repressed genes
becomes aberrantly expressed. These findings pro-
vide insights into the regulatory role of CHD5 during
neurogenesis and suggest how inactivation of this
candidate tumor suppressor might contribute to
neuroblastoma.
INTRODUCTION
The process of neurogenesis is characterized by a gradual loss
of progenitor properties and the acquisition of specific neuronal
traits (Molyneaux et al., 2007). This is accompanied by a progres-
sive restriction on possible alternative cellular fates. The instruc-
tive and inductive roles played by DNA-binding transcription
factors in the acquisition of differentiated neuronal properties
are well characterized (Bertrand et al., 2002; Molyneaux et al.,
2007). However, less is known about how gene programs ofDevelopalternative lineages are silenced. Furthermore, the precise roles
of chromatin regulators during neuronal lineage specification
remain largely unexplored.
Chromatin regulators are generally considered to act as facili-
tators of lineage specification, rather than actually directing the
process (Holmberg and Perlmann, 2012). Several different
classes of chromatin regulators, such as those involved in
‘‘writing’’ and ‘‘reading’’ histone posttranslational modifications,
havebeenshown tobecentrally involved in geneexpression con-
trol during lineage specification (Kouzarides, 2007; Schu¨beler,
2009). For example, the Polycomb and Trithorax group proteins
are very well characterized regulators of cell-fate decisions that
act antagonistically during development (Bracken and Helin,
2009; Pietersen and van Lohuizen, 2008). EZH2, a component
of Polycomb Repressive Complex 2 (PRC2), is a ‘‘writer’’ protein
that, together with SUZ12 and EED, mediates trimethylation of
histone H3 at lysine 27 (H3K27me3), a mark associated with
gene repression (Margueron and Reinberg, 2011). In contrast,
several writers within the Trithorax family mediate the deposition
of H3K4me3, a mark generally associated with gene activation
(Schuettengruber et al., 2011). Chromatin ‘‘reader’’ proteins
regulate gene expression by binding to, or reading, posttransla-
tionally modified histone proteins (Taverna et al., 2007). Their
interactions with histone N-terminal tails are mediated by
conservedstructural domains suchaschromodomains, plant ho-
meodomains (PHDs), and Tudor domains (Yap and Zhou, 2010).
The CHD1–9 family of reader proteins is defined by the pres-
ence of two N-terminal chromodomains and a helicase-like
ATPase motif associated with nucleosome remodeling (Clapier
and Cairns, 2009). Several members of this family have been
suggested to play key roles during development (Ho and Crab-
tree, 2010). For example, CHD1 has a crucial role in regulating
embryonic stem cell (ESC) pluripotency by maintaining the
‘‘open chromatin state’’ that is characteristic of pluripotent cells
(Gaspar-Maia et al., 2009). This function of CHD1 is partlymental Cell 26, 223–236, August 12, 2013 ª2013 Elsevier Inc. 223
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to H3K4me3 (Flanagan et al., 2005; Simic et al., 2003). Similarly,
CHD7 binds H3K4me1 via its chromodomains and has been
reported to be required for controlling the active state of distal
enhancer elements within the neural crest lineage (Bajpai et al.,
2010; Schnetz et al., 2009).
CHD reader proteins in the CHD3–5 subgroup are uniquely
defined by their double PHD domains, in addition to their double
chromodomains (see Figure 4A). Although the PHD domains of
CHD4 and CHD5 have been shown to bind unmodified H3K4,
very little is known about the histone-binding specificity of the
double chromodomains of these proteins (Musselman et al.,
2009; Paul et al., 2013). Both CHD3 and CHD4 are members of
the multiprotein nucleosome remodeling and deacetylase
(NuRD) complex, which was originally identified as a transcrip-
tional repressor (McDonel et al., 2009). Interestingly, the histone
deacetylation activity of CHD4NuRD-containing complexes was
recently shown to facilitate the recruitment of PRC2 components
and subsequent deposition of H3K27me3 at target genes
(Reynolds et al., 2012). Consistent with this, dMI-2, the closest
CHD3–5 protein homolog in Drosophila, synergizes with Poly-
comb group proteins to maintain the repressed state of certain
homeotic genes during larval development (Kehle et al., 1998).
However, other studies suggest that the CHD3–4 proteins may
also modulate transcription at active genes (Reynolds et al.,
2013). For example, the dMI-2 protein colocalizes with RNA
Polymerase II on sites of actively transcribed genes inDrosophila
(Murawska et al., 2008), and chromatin immunoprecipitation
sequencing (ChIP-seq) analysis of CHD4 indicates that it binds
to the gene loci of a large number of active genes in mouse
ESCs and lymphocytic progenitor cells (Hu and Wade, 2012).
The CHD5 gene resides within a chromosomal region span-
ning 23 genes at 1p36, which commonly exhibits loss of hetero-
zygosity in high-risk neuroblastoma (Brodeur, 2003; Okawa
et al., 2008). In fact, CHD5 has been proposed to be the key
tumor-suppressor gene within this locus (Bagchi et al., 2007).
Neuroblastomas are thought to originate from neural-crest-
derived precursor cells of the sympathetic neuronal lineage (Bro-
deur, 2003). CHD5 is expressed in normal neuronal tissues and in
low-risk neuroblastomas, but its expression levels are signifi-
cantly reduced in tumors from high-risk neuroblastoma patients
(Fujita et al., 2008; Garcia et al., 2010). Notably, ectopic expres-
sion of CHD5 abrogates the growth of neuroblastoma cell lines
both in vitro and in xenografts (Fujita et al., 2008). However,
very little is known about the role of CHD5 during neuronal differ-
entiation, and in particular, how its loss might contribute to the
development of neuroblastoma. In this study, we show that
CHD5 is required for terminal neuronal differentiation and has a
dual role in facilitating both the activation of neuronal genes
and the repression of a cohort of Polycomb target genes.
RESULTS
Expression of Chd5 Is Activated in Late-Stage
Progenitors and Is Maintained in Terminally
Differentiated Neurons
Previously, CHD5 was shown to be predominantly expressed in
the adult CNS (Garcia et al., 2010; Potts et al., 2011). To further
evaluate its pattern of expression, we performed quantitative224 Developmental Cell 26, 223–236, August 12, 2013 ª2013 ElsevieRT-PCR (qRT-PCR) and western blot analysis in multiple mouse
tissue types, and found it to be expressed in the brain and, albeit
to a lesser degree, in the retina and adrenal gland (Figures 1A and
1B). To acquire a detailed view of the spatial distribution and cell-
type specificity of Chd5 expression, we developed CHD5-spe-
cific antibodies for immunofluorescent staining (Figures S1A–
S1C available online) and observed abundant nuclear CHD5
staining in NEUN+ neurons of the neocortex (Figure 1C), but not
in surrounding astrocytes or oligodendrocytes (Figures 1D and
1E). A neuron-specific staining pattern was also observed in
both the retina (Figure S1D) and adrenal gland, where CHD5
immunoreactivity is restricted to TUJ1+ neuroendocrine cells
(Figure 1F; Figure S1E). The pattern ofChd5 expression suggests
that CHD5 is a neuron-specific chromatin remodeler with roles in
both the CNS and peripheral tissues of neural origin.
In order to explore the temporal onset of CHD5 expression
during adult neurogenesis, we performed immunofluorescent
staining in the adult mouse hippocampus, where we observed
an extensive overlap of CHD5 with NEUN (Figure 1G). A minor
population of CHD5-positive cells lacking NEUN staining was
also detected (Figure 1G, inset). The position in the neurogenic
subgranular zone (SGZ) suggested that these cells were
neuronal progenitors. To determine the identity of these cells,
we performed staining with antibodies specific for different
progenitor states (Figures 1H–1K). We observed no overlap
between CHD5 and the early SGZ type 1 stem cell marker,
GFAP (Figure 1H). However, a significant number of CHD5
expressing cells also expressed high levels of DCX (Figure 1I),
a marker for the type 2b and type 3 intermediate- to late-stage
progenitors (Breunig et al., 2007). Because DCX expression per-
sists in postmitotic immature granule cells (GCs), we also stained
for the mitotic marker phospho-histone 3 (pH3). The colocaliza-
tion of pH3 and DCX in a subpopulation of the CHD5-positive
cells suggests a late-stage progenitor identity for this cell popu-
lation (Figure S1F). Supporting this, we detected a subpopula-
tion of CHD5-expressing cells, which also expressed the neural
progenitor marker SOX3 (Figure 1J). Triple staining of bromo-
deoxyuridine (BrdU) pulse chase experiments confirmed that a
cohort of the CHD5+/SOX3+ cell population had incorporated
BrdU 24 hr after injection (Figure 1K), suggesting that this cell
population had exited the cell cycle in the previous 24 hr. The
lack of BrdU staining in animals sacrificed 2 hr after BrdU injec-
tion (data not shown) implies that CHD5 is not expressed in
rapidly proliferating progenitors. Taken together, these data
suggest that CHD5 is upregulated during terminal differentiation
of late-stage neuronal progenitors.
Chd5 Is Required for Terminal Differentiation
of Embryonic Cortical Neurons
Wenext wished to investigate the role of CHD5 during embryonic
neurogenesis. The vast majority of murine cortical neurons are
generated between embryonic day 10 (E10) and E18 (Molyneaux
et al., 2007). Consistent with our observations in the adult CNS,
we found CHD5 to be expressed throughout cortical and spinal
cord development as cells downregulated progenitor properties,
exited the cell cycle, and acquired a terminally differentiated
neuronal identity (Figure 1L; Figures S2A–S2D).
To analyze the consequences of Chd5 knockdown in the
developing neocortex, we designed two GFP-expressing smallr Inc.
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Figure 1. CHD5 Is a Pan-Neuronal Marker that Is Upregulated during Late-Stage Neurogenesis
(A) Western blot of CHD5 and histone H3 in tissues derived from P10 mice pups.
(B) qRT-PCR of Chd5 and NeuN (Fox-3) mRNA levels in tissues from P10 mice pups. Error bars indicate the SD of triplicate qPCR data.
(C–E) Staining in the adult mouse cortex of CHD5 (red) and the neuronal marker NEUN (green in C), the astrocytic marker S100B (green in D), and the
oligodendrocytic marker APC (green in E).
(F) CHD5 protein (red) specifically localizes to the neuroendocrine portion of the adrenal gland. Phalloidin (green) staining is used to discriminate between the
adrenal medulla and the actin-rich adrenal cortex.
(G) Themajority of CHD5+ cells (red) in the DG of the hippocampus are differentiated NeuN+ (green) neurons. The inset shows that a small subpopulation of Chd5+
cells is NEUN (arrow in inset).
(H) GFAP+ (green) astrocytes or stem cells in the DG are CHD5 (red).
(I) A subpopulation of DCX+ (green) progenitor cells are also CHD5+ (red).
(J) Several SOX3+ (green) neural stem/progenitor cells are also CHD5+ (red).
(K) A subpopulation of the SOX3+/CHD5+ cells in (J) have incorporated BrdU (green) after a 24 hr pulse chase experiment (arrows in insets J and K).
(L) Prominent CHD5 (red) expression is evident in the CP of E16.5 mouse neocortex, but not in the majority of SOX3+ (green) stem cells of the VZ.
CP, cortical plate; DG, dentate gyrus; VZ, ventricular zone. See also Figure S1.
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The Role of CHD5 during Neurogenesishairpin RNA (shRNA) vectors (shChd5.1 and shChd5.2) directed
against Chd5. We electroporated them or a shCtrl-Gfp control
vector in utero into the developing E14.5 cortex and
subsequently analyzed the embryos at E18.5 (Figure 2; Figures
S2E and S2F). In the embryos electroporated with shCtrl-Gfp,
GFP-positive cells were distributed along the growing cortex
from the ventricular zone (VZ) all the way out to the pial surface,
and the majority expressed CHD5 (Figure 2A). In contrast, in
shChd5.1-Gfp or shChd5.2-Gfp electroporated cortices, a near
complete lack of overlap between GFP and CHD5 was evident,
indicating efficient knockdown of CHD5 (Figures 2B and 2C;Developdata not shown). The knockdown of CHD5 was accompanied
by a severe failure of cells to exit the germinal VZ, SVZ, and inter-
mediate zone (Figures 2B). In the shCtrl-Gfp embryos, the over-
lap with SOX3 was minimal, whereas among the shChd5-Gfp
electroporated cells, almost 30% were SOX3+ (Figures 2D–2F).
In addition, there was a slight but significant increase in the num-
ber of cells expressing the cell-cycle marker KI67 in the
shChd5.1-Gfp electroporated cells (Figures 2G–2I). The deeper
cortical layers V–VI are generated earlier than the electroporated
cells. Accordingly, a cohort of shCtrl-Gfp-expressing cells
migrated through these deep layers without expressing themental Cell 26, 223–236, August 12, 2013 ª2013 Elsevier Inc. 225
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Figure 2. CHD5 Is Required for Neuronal Differentiation of Embryonic Cortical Neurons
(A) In utero electroporated shCtrl-Gfp expressing cells (green) exit the VZ/SVZ, migrate out into the cortical layers, and upregulate CHD5 (red) expression.
(B) Cells electroporated with shChd5-Gfp (green) remain in the VZ/SVZ or IZ and do not upregulate CHD5.
(C) Quantification of shCtrl-Gfp and shChd5-Gfp electroporated cells in utero, displaying the percentage of GFP-positive cells that are also positive for CHD5.
(D and E) ShCtrl-Gfp-expressing cells downregulate the neural stem/progenitor cell marker SOX3 (red, E) as they exit the VZ/SVZ (D). A significant proportion of
shChd5-Gfp-expressing cells (green) retain expression of SOX3 (red).
(F) Quantification of the percentage of GFP+/SOX3+ cells in shCtrl and shChd5-Gfp electroporated mice.
(G–I) An increased number of KI67+ cells (red) in shChd5-Gfp expressing cells (H and I) in comparison to control electroporated cells (G and I).
(J and K) Cell migration through the TBR1+ (red) deeper layers V–VI was unperturbed in the shCtrl electroporated embryos (J), but significantly reduced in
shChd5-Gfp electroporated embryos (K).
(L) Quantification of the percentage of GFP+ cells migrating through V–VI.
(M) The shCtrl-Gfp electroporated cells (green) reach layers II–IV and upregulate expression of the layer-specific neuronal marker SATB2 (red).
(N) The shChd5-Gfp electroporated cells (green) remain in the IZ/SVZ/VZ, not expressing SATB2 (red).
(O) Quantification of the percentage of GFP+ cells that are SATB2+.
(P) Robust expression of the pan-neuronal marker MAP2 (red) in the cells expressing shCtrl-Gfp.
(Q) Cells expressing shChd5.2-Gfp fail to upregulate MAP2 expression.
(R) Quantification of the percentage of GFP+ cells that are MAP2+.
IZ, intermediate zone; PS, pial surface; SVZ, subventricular zone; VZ, ventricular zone. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001,
Student’s t test, n = 4. See also Figure S2.
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The Role of CHD5 during Neurogenesislayer-specific marker TBR1 (Figure 2J). In contrast, the
shChd5.1-Gfp-expressing cells showed significantly reduced
migration through layers V–VI (Figures 2K and 2L).
A substantial number of the shCtrl-Gfp-expressing cells
reached layers II–IV and expressed SATB2, a transcription factor
that distinguishes these upper layers from the deeper layers (Fig-
ure 2M). However, virtually no cells expressing shChd5.1-Gfp
reached layers II–IV, and consequently there was a significant
reduction of GFP+/SATB2+ cells in layers II–IV (Figures 2N and
2O). We also stained with an antibody specific for the pan-226 Developmental Cell 26, 223–236, August 12, 2013 ª2013 Elsevieneuronal protein MAP2 and observed an abundant colocaliza-
tion of GFP and MAP2 in the control electroporated cortices
(Figure 2P), whereas the shChd5.1-Gfp electroporated cortices
displayed severely reduced numbers of GFP+ cells that ex-
pressed MAP2 (Figures 2Q and 2R). This suggests that the
defect is not the result of precocious generation of neurons
within the germinal zone of the shChd5.1-Gfp-treated cortices
or of defective radial migration. These undifferentiated cells
also lacked detectable cleaved Caspase 3, suggesting that
apoptotic pathways were not activated (data not shown). Takenr Inc.
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Figure 3. CHD5 Is Required during In Vitro Neurogenesis for Activation of the Neurogenic Gene Expression Program and the Maintained
Repression of Polycomb Target Genes
(A) Flow diagram depicting the knockdown strategy for CHD5 in a model of in vitro derivation of CNS neurons from mouse E14 ESCs.
(B) qRT-PCR analysis of ESCs, NPCs (day 0), and cells during terminal differentiation (day 3 and day 5), infected with scrambled shRNA (C) or with aChd5 shRNA
(5), showing the relative expression ofChd5, Pax6 (a marker of neural progenitors),Nanog (a marker of ESCs),NeuN (a marker of neurons),Dner,Ncam, and Ebf1.
Error bars indicate the SD of triplicate qPCR data.
(C) Tree-view representation of gene expression microarray data depicting the genes whose expression increases in shCtrl-infected cells, but not in shChd5-
infected cells.
(D) GO analysis of the gene list from (C).
(E) Tree-view representation of gene expression microarray data depicting the genes whose expression increased in shChd5-infected cells, but not in shCtrl-
infected cells.
(F) Venn diagram analysis representing a 4-fold enrichment of H3K27me3 promoter-positive genes in the cohort of genes upregulated inChd5-depleted cells (E).
The expected values were calculated based on a previously reported genome-wide data set (Mohn et al., 2008).
See also Figure S3.
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minal neuronal differentiation and that cells lacking appropriate
CHD5 levels remain within the progenitor zone, retaining key pro-
genitor properties.
Knockdown of Chd5 Results in Failure to Upregulate
Neuronal Genes
To address the mechanisms by which CHD5 facilitates neuronal
differentiation, we used an in vitro model of neurogenesis (Fig-
ure S3A; Bibel et al., 2007). Chd5 messenger RNA (mRNA)
expression increased during differentiation of mouse ESCs into
neurons (Figures S3B and S3C), consistent with our in vivo
observations. We next transduced ESCs with either shCtrl orDevelopone of two Chd5 targeting vectors, shChd5, and induced cells
to undergo neurogenesis (Figure 3A). The ESCs infected with
shChd5, were capable of differentiating toward neural progenitor
cells (NPCs), as indicated by the upregulation of Pax6. However,
the reduced levels of Chd5 led to a failure to further differentiate
into neurons and this correlated with a failure to activate the
expression of several canonical neuronal genes, including
Tubb3, NeuN (Fox-3), and Ncam (Figure 3B). To understand
the genome-wide consequences of Chd5 knockdown during
neuronal differentiation, we performed expression microarrays
of shCtrl- and shChd5-infected cells (Figure 3C). This revealed
that 512 genes were activated in control cells but not in the
Chd5-depleted cells. A Gene Ontology (GO) analysis of thesemental Cell 26, 223–236, August 12, 2013 ª2013 Elsevier Inc. 227
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Figure 4. CHD5 Binds to the Polycomb-Mediated H3K27me3 Mark via Its Tandem Chromodomains
(A) Organization of the conserved domains within five distinct chromodomain helicase DNA-binding (CHD) proteins.
(B) Characterization of the association of the CHD5 protein with modified histone tails. Peptide pull-downs were performed on mouse brain nuclear lysates using
biotin-tagged modified histone H3 peptides. Western blots were performed for CHD5, EZH2, and HP1g as indicated.
(C) Peptide pull-downs of recombinant Flag-tagged wild-type and mutant histone-binding domain fragments of CHD5 and CHD1 expressed in HEK293 cells.
(D) Peptide pull-downs of recombinant GST-tagged wild-type and mutant histone-binding domain fragments of CHD5 and CHD1.
(E) Representative SPR sensorgrams for a GST-tagged peptide corresponding to the double-chromodomain portion of the CHD5 protein on both unmodified H3
peptides and H3K27me3-modified peptides. The affinity rate constants were determined from a concentration series of wild-type CHD5 fragment binding to
H3K27me3.
See also Figure S4.
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The Role of CHD5 during Neurogenesisgenes revealed a striking enrichment of factors involved in late-
stage neuronal differentiation (Figure 3D). This included genes
with roles in the regulation of synapse development, neuron pro-
jection, and neurotransmitter transport, such as NeuroD2, Dner,
and Ebf1.
Knockdown of Chd5 Results in an Upregulation
of Polycomb Target Genes
We also identified a smaller cohort of 119 genes that were aber-
rantly activated in Chd5-depleted cells (Figure 3E; Figure S3D).
Strikingly, 50 of these genes were previously reported to
possess H3K27me3 on their promoters in neurons derived by
the same protocol (Mohn et al., 2008), representing a 4-fold
enrichment over that expected (Figure 3F). Furthermore, there
was a paucity of H3K4me3 promoter-positive genes within the
119 upregulated genes (Figure 3F), again supporting the idea
that these genes are ordinarily not expressed during normal neu-
rogenesis. These results suggested that CHD5might functionally
interact with Polycombs during neurogenesis and were reminis-
cent of the reported functional interplay between dMI-2 and
Polycomb in Drosophila (Kehle et al., 1998). Interestingly, the
cohort of Polycomb target genes that were upregulated in
Chd5-depleted cells was strikingly rich in factors characteristic228 Developmental Cell 26, 223–236, August 12, 2013 ª2013 Elsevieof nonneuronal lineages derived from the extraembryonic, meso-
dermal, and endodermal germ layers (Figure 3E; Figure S3D).
Taken together, these data suggest that proper differentiation
along the neuronal lineage is dependent on the capacity of
CHD5 to facilitate the activation of neuronal gene expression
and to maintain the repression of a small cohort of Polycomb-
repressed genes.
CHD5 Binds to H3K27me3 via Its Tandem
Chromodomains
To investigate the function of the histone-binding domains of
CHD5 (Figure 4A), we performed peptide pull-down assays on
nuclear lysates generated from either mouse cortices or human
SH-SY5Y neuroblastoma cells, and found that endogenous
CHD5 protein was enriched on an H3K27me3 peptide compared
with an unmodified H3 peptide (Figure 4B; Figure S4). The HP1g
protein strongly bound to H3K9me3, whereas EZH2 was prefer-
entially enriched on H3K27me3, as expected (Bannister and
Kouzarides, 2011). To further explore the apparent binding pref-
erence of CHD5 to the H3K27me3 modification, we then per-
formed peptide pull-downs of whole-cell lysates from HEK293
cells transfected with FLAG-tagged recombinant proteins repre-
senting the histone-binding regions of CHD5 (Figure 4C). Thisr Inc.
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both necessary and sufficient to mimic the H3K27me3 binding
preference of the full-length CHD5 protein, and that, as ex-
pected, a CHD1 fragment enriched on the H3K4me3 peptide.
Notably, CHD5 fragments with point mutations in either of the
two chromodomains had reduced affinity to the H3K27me3
peptide (Figure 4C).
We next purified recombinant glutathione S-transferase (GST)
fusion protein fragments, representing the putative histone-
binding domain regions of CHD5 and CHD1, and performed
peptide pull-downs in a cell-free context (Figure 4D). The GST-
tagged wild-type CHD5 fragment bound to the H3 peptide and
preferentially bound H3K27me3 (Figure 4D). Interestingly, this
fragment did not bind to the H3K4me3 peptide, consistent
with the previous demonstrated ability of the PHDs of CHD5 to
discriminate against H3K4 when it is in the trimethylated state
(Paul et al., 2013). Importantly, the control GST-CHD1 fragment
enriched on the H3K4me3 peptide (Figure 4D). We tested an
equivalent CHD5 fragment with two point mutations (one in
each chromodomain), denoted GST-CHD5 (L518A/Y619E),
and found that it displayed a loss of preferential enrichment on
the H3K27me3 peptide compared with the unmodified H3
peptide. Finally, in order to directly test the ability of the CHD5
chromodomains to bind H3K27me3, we generated another
recombinant protein, denoted GST-CHD5-chromodomains
(representing only the two chromodomains of CHD5), and
performed surface plasmon resonance (SPR) to accurately
measure its in vitro binding to H3K27me3 and unmodified H3
peptides (Figure 4E). This analysis revealed that the binding of
GST-CHD5-chromodomains to H3K27me3 was highly repro-
ducible, with an apparent KD of 1 nM, as determined from
independent measurements at four different concentrations of
the protein. Taken together, these data demonstrate that
CHD5 depends on its chromodomains for its ability to read the
H3K27me3 modification.
Genome-wide ChIP-Seq of CHD5 Reveals that
It Is Associated with a Large Cohort of Genes
To explore a possible role of CHD5 in regulating gene expres-
sion, we performed a genome-wide analysis of CHD5 localiza-
tion. We utilized human SH-SY5Y neuroblastoma cells, which
retain both alleles of CHD5 and respond to retinoic acid (RA)
treatment with upregulation of CHD5 expression and concomi-
tant acquisition of differentiated neuronal properties (FigureS5A).
To unequivocally confirm the specificity of our CHD5 antibody,
we took advantage of a biotin-tagging strategy for performing
ChIP experiments, known as bioCHIP (Kim et al., 2009). SH-
SY5Y cells expressing biotin ligase (BirA) were transfected with
either a plasmid expressing Avidin-tagged CHD5 (FBio-CHD5)
or a control empty vector (FBio-Ctrl). ChIP-seq with our endog-
enous CHD5 antibody was performed in parental RA-treated
SH-SY5Y cells, whereas bioChIP-seq was performed in both
the FBio-Ctrl- and FBio-CHD5-expressing, RA-treated SH-SY5Y
cell lines, respectively. This analysis, represented in heatmap
format, demonstrated that the binding profile of the endogenous
CHD5ChIP-seq experiment was highly comparable to that of the
bio-CHD5 ChIP-seq experiment (Figure 5A). Interestingly, the
pattern of CHD5 binding varied from gene to gene, but was
generally broadly localized across gene loci (Figure 5B). Surpris-Developingly, despite our demonstration of the ability of the chromodo-
mains of CHD5 to bind to the H3K27me3mark (Figure 4), thema-
jority of CHD5 target genes lacked H3K27me3 (Figure 5A). In
total, CHD5 bound around the promoter regions of 12,220 genes
without H3K37me3, while another 708 CHD5-bound genes were
focally enriched with H3K27me3 on their promoters. Intriguingly,
a GO analysis of this cohort of 708 CHD5/H3K27me3 double-
positive genes revealed that they were primarily enriched for
transcriptional regulators and genes involved in developmental
signaling pathways of nonneuronal lineages, most prominently
of the mesodermal germ layer (Figure S5B). In contrast, the
CHD5-only genes were most significantly enriched for genes of
the nerve-growth-receptor signaling pathway. To validate the
ChIP-seq experiments, we performed independent ChIP-qPCR
experiments and confirmed CHD5 binding on five CHD5-only
and ten CHD5/H3K27me3 double-positive genes, but not on
two H3K27me3-only genes (Figure 5C).
CHD5 Associates with Neuronal Genes and Is Required
for Their Activation during Neurogenesis
To determine whether the presence of CHD5 on genes encoding
neuronal regulators is required for their activation during neuro-
genesis, we stably transduced SH-SY5Y neuroblastoma cells
with either shCtrl or shCHD5 constructs and treated them for
8 days with 10 mM RA (Figure 6A). In contrast to the shCtrl-
transduced cells, SH-SY5Y cells transduced with the shCHD5
construct did not upregulate CHD5 or TUBB3 expression after
RA treatment (Figures 6B and 6C). They instead maintained a
high rate of proliferation and failed to acquire a neuronal
morphology (Figure 6A). This suggested that CHD5 is required
for neuronal differentiation of human neuroblastoma cells and
is consistent with our earlier observations of a similar require-
ment both in the developing murine neocortex and in mouse
ESCs (Figures 2 and 3).
We next tested themRNA expression levels of three additional
CHD5-only target genes that are known to be expressed within
the differentiating sympathoadrenal lineage: PHOX2A, RARA,
and TBX2 (Boskovic and Niles, 2004; Harrelson and Papaioan-
nou, 2006; Joshi et al., 2006). These genes were all upregulated
in the shCtrl cells after RA treatment, but not in the CHD5-
depleted cells (Figure 6C). We also performed CHD5 and
H3K27me3 ChIP-qPCRs on these genes and found that the
association of CHD5 on their promoters correlated with their
upregulation during neurogenesis (Figure 6D). Taken together
with our previous experiments, these results suggest that
CHD5 is required to facilitate the activation of the several crucial
neuronal genes and is directly associated with their gene loci
during neuronal differentiation.
The Association of CHD5 with a Cohort of Polycomb
Target Gene Loci Is Necessary to Maintain Their
Repressed State during Neurogenesis
To explore the potential role of CHD5 in the repression of Poly-
comb target genes, we monitored the mRNA expression of
four CHD5/H3K27me3 double-positive genes (HES7, DLX2,
WNT7A, and EPAS1) before and after RA treatment in shCtrl
and shCHD5 cells (Figure 6E). Strikingly, all four genes were
aberrantly activated in the absence of CHD5. This correlated
with depletion of CHD5 on their gene promoters and amental Cell 26, 223–236, August 12, 2013 ª2013 Elsevier Inc. 229
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Figure 5. Genome-wide ChIP-Seq Analysis of CHD5 and H3K27me3 in Differentiated SH-SY5Y Cells
(A) Heatmap representation of the read frequency (±5 kb around all transcription start sites) obtained from ChIP-seq and bioChIP-seq experiments of input DNA
(FBio-CHD5 expressing SH-SY5Y cells), bio-Ctrl, K27me3 (FBio-CHD5 expressing SH-SY5Y cells), bio-Chd5, and endogenous CHD5 (SH-SY5Y cells). All cells
lines were treated with 10 mM RA for 8 days prior to ChIP experiments.
(B)Representativeexamplesofbio-CHD5andH3K27me3ChIP-seq tracks for the four indicatedCHD5targetgenes. TheCCNB2gene isshownasanegativecontrol.
(C) ChIP and bioChIP qPCR validation analysis with the indicated antibodies on a panel of CHD5 target genes in differentiated FBio-CHD5-expressing SH-SY5Y
cells. The precipitated DNA was analyzed by qPCR with primers corresponding to the promoter regions of the indicated genes and presented as the percentage
of protein bound, normalized to input. Error bars indicate the SD of triplicate qPCR data.
See also Figure S5.
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results are consistent with three previous studies that estab-
lished that CHD4, or other members of the NuRD complex, are230 Developmental Cell 26, 223–236, August 12, 2013 ª2013 Elsevierequired for the sustained association of Polycombs on a cohort
of cobound target genes in different cell types (Morey et al.,
2008; Reynolds et al., 2012; Sparmann et al., 2013) We nowr Inc.
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Figure 6. CHD5 Is Required for Differentiation of SH-SH5Y Cells, Activation of Neuronal Genes, and Repression of Polycomb Target Genes
(A) Phase-contrast microscopy of SH-SY5Y cells infected with either shCtrl- or shCHD5-expressing lentivirus and induced to differentiate for 8 days in the
presence of 10 mM RA.
(B) qRT-PCR analysis of CHD5 mRNA levels in shCtrl- and shCHD5-infected SH-SY5Y cells before and after 8 days of differentiation in RA.
(C) qRT-PCR analysis of the indicated CHD5 target genes in the presence or absence of CHD5, before and after RA-induced differentiation.
(D) ChIP analysis with the indicated antibodies on the same genes as in (C).
(E) qRT-PCR analysis of the indicated double-positive CHD5/H3K27me3 genes before and after RA-induced differentiation in the presence or absence of CHD5.
(F) ChIP analysis with the indicated antibodies on the same genes as in (E).
Error bars indicate the SD of triplicate qPCR data.
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Figure 7. The Chromodomains of CHD5 Are Required for Its Role
during Embryonic Cortical Differentiation
(A–C) In utero electroporated shCtrl-Gfp-expressing cells (green) migrate into
the cortical plate through the TBR1+ (red) layers V–VI (A). This pattern of dif-
ferentiation is not disrupted by combined expression with shCtrl-Gfp and the
wild-type full-length human CHD5, CHD5-FL (B), or with the mutated CHD5
construct, CHD5L518/Y619E (C).
(D) Cells electroporated with shChd5.2-Gfp (green) do not migrate into the
TBR1+ (red) cortical plate.
(E) The expression ofCHD5-FLwith shChd5.2-Gfp restores a normal pattern of
differentiation.
(F) The expression of CHD5L518/Y619E fails to rescue the shChd5.2-Gfp
phenotype.
(G) Quantification of the percentage of GFP+ cells that are located in the
cortical plate, as determined by the TBR1+ region and above (dashed line
in A–F).
Data are represented as mean ± SEM. **p < 0.01, ***p < 0.001, ANOVA with a
Newman-Keuls multiple-comparisons posttest, n = 5–12.
Developmental Cell
The Role of CHD5 during Neurogenesisdemonstrate that CHD5, like CHD4, is required to facilitate the
deposition of H3K27me3 on a cohort of Polycomb target genes
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To determine whether the H3K27me3-binding chromodomains
are important for the functional role of CHD5 during neuronal
differentiation, we performed an in vivo rescue experiment with
double electroporations at E14.5, with either shCtrl-Gfp or
shChd5.2-Gfp, in combination with a vector expressing either
wild-type human full-length CHD5 (CHD5-FL) or a full-length
CHD5 mutant with two amino acid substitutions within the
chromodomains, which are required for binding H3K27me3
(CHD5-L518A/Y619E). We observed that neither CHD5-FL nor
CHD5-L518A/Y619E had any detectable effect on the shCtrl-
Gfp-expressing cells (Figures 7A–7C and 7G). The fact that over-
expression of CHD5-FL did not promote premature cell-cycle
exit or induce neuronal differentiation suggests that CHD5 lacks
inductive capacity and plays a more permissive, albeit essential,
role during neurogenesis (Figure 7B). The combined electropora-
tion of CHD5-FL with shChd5.2-Gfp efficiently rescued the
CHD5 knockdown phenotype (Figures 7D, 7E, and 7G). In
contrast, CHD5-L518A/Y619E failed to restore a normal pattern
of neuronal differentiation when it was coelectroporated with
shChd5.2-Gfp, even though it was expressed at levels compara-
ble to those observed for the CHD5 FL construct (Figures 7F and
7G; data not shown). These results suggest that the chromodo-
mains of CHD5, and possibly their interaction with H3K27me3,
are required for terminal neuronal differentiation.
DISCUSSION
Here we report that the chromatin remodeler CHD5 is required
for terminal differentiation of neuronal progenitors. Genome-
wide ChIP-seq analysis revealed that CHD5 binds a large cohort
of genes and is required to facilitate the activation of neuronal
genes during neuronal differentiation. We also show that the
localization of CHD5 on a cohort of Polycomb target genes is
necessary to maintain their repressed state. The chromodo-
mains of CHD5 bind to H3K27me3 and are essential for neuro-
genesis. Taken together, our data support a model in which
CHD5 has a permissive but essential role during neurogenesis,
in which it both facilitates the activation of neuronal genes and
synergizes with Polycomb group proteins to facilitate the repres-
sion of genes encoding regulators of alternative lineages.
We observed that the overexpression of CHD5 failed to pro-
mote neurogenesis (Figure 7B), suggesting that it lacks the
inductive capacity of proneural bHLHs such as Ascl1 and Neuro-
genin 2 (Bertrand et al., 2002). Interestingly, the Trithorax group
protein MLL1, which also lacks instructive ability, was shown to
facilitate activation of the proper gene expression program dur-
ing neurogenesis (Lim et al., 2009). It is not known how CHD5
and MLL1 are recruited to their target genes. However, it may
involve the associationwith lineage-specific transcription factors
and/or long noncoding RNAs. The precise mechanism(s) by
which CHD5 (and CHD3 and CHD4, for that matter) facilitates
the activation of gene expression remain unclear. One hypothe-
sis is that the associated histone deacetylase (HDAC) activity of
NuRD-like complexes is required to suppress spurious tran-
scription initiation on actively transcribed genes (Reynolds
et al., 2013). Another idea is that NuRD and CHD5-NuRD-like
complexes may be associated with genes in order to ‘‘prime’’r Inc.
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proteins are involved in the ‘‘dampening’’ of expression on these
active genes, and their failure to become activated is the sec-
ondary consequence of the inappropriate activation of other
CHD5 target genes (Reynolds et al., 2012). It is clear that the
role of CHD3–5 and dMI-2 on active gene loci requires further
investigation.
We also demonstrate that CHD5 is required for the silencing of
a cohort of Polycomb target genes. This functional interplay
between CHD5 and Polycombs may be part of an evolutionary
conserved process. For example, the Drosophila dMI-2 and
mammalian CHD4 proteins both functionally interact with Poly-
combs to maintain the repressed state of certain genes (Kehle
et al., 1998; Reynolds et al., 2012; Sparmann et al., 2013).
Some mechanistic clues as to the nature of this interplay have
come from recent work by Reynolds et al. (2012), who showed
that the loss of NuRD-mediated histone deacetylation activity
in Mbd3 null cells correlated with a loss of JARID2 and SUZ12
association on CHD4 target genes. The authors speculated
that the deacetylation activity of NuRD is required for the depo-
sition of PRC2-mediated H3K27me3. Since CHD5 has also been
shown to be part of a large multiprotein complex containing
MBD3 and HDAC2 (Potts et al., 2011), it is possible that CHD5
also recruits deacetylase activity to Polycomb target genes. In
support of such a role for a CHD5 complex in the mediation
of H3K27me3, we show that the depletion of CHD5 leads to a
loss of H3K27me3 on the gene loci of CHD5/H3K27me3
double-positive genes (Figure 6).
The binding ofCHD5 toH3K27me3 suggests that it contributes
to the silencing of nonneuronal genes (Figure 4). We show that a
CHD5proteinwith twopointmutations in its two chromodomains
was incapable of rescuing neurogenesis in the developing
neocortex (Figure 7). CHD5 contains two PHDs and two chro-
modomains, which we propose act synergistically to deter-
mine its histone-binding specificity. CHD5 preferentially binds
H3K27me3 andmutation of either of its two chromodomains per-
turbs this preference. It is likely that the residual binding capacity
of CHD5 to histone H3 is mediated by its PHDs, as reported
previously (Paul et al., 2013). Consistent with this, both chromo-
domain mutants retain their ability to discriminate against the
H3K4me3 mark and bind the H3 tail. Two key features of this
work on the histone binding are worth highlighting. First, we
assayed the combined histone readingmodule of CHD5 simulta-
neously. Second, andcrucially,weperformed thebinding studies
with custom synthesized peptides that contained both the H3K4
and H3K27 epitopes (H3; amino acids 1–40), thereby allowing
both the PHD and chromodomains to interact with the peptide.
This allowed us to show that the N-terminal region of CHD5 con-
stitutes a multivalent histone recognition cassette, with indepen-
dent histone reading functions attributed toboth the tandemPHD
and tandem chromodomains. Given the structural similarities
between CHD5 and CHD3/CHD4, this implies that the chro-
modomains of the CHD3 and CHD4 proteins might have similar
importance for their respective functions.
Our results also have implications for our understanding
of neuroblastoma. We speculate that the loss of CHD5 con-
tributes to tumor formation, at least in part, by rendering neuro-
blasts incapable of undergoing terminal differentiation. Sup-
porting this, the ability of human neuroblastoma cells toDevelopundergo neuronal differentiation upon prolonged exposure to
RA is associated with retained 1p36 status (Figure S5A).
Indeed, the knockdown of CHD5 in SH-SH5Y neuroblastoma
cells led to a complete block in their ability to undergo RA-
induced differentiation and a failure to upregulate neuronal
gene expression (Figures 6A and 6C). RA treatment has been
shown to improve survival in certain treatment regimens of
neuroblastoma (Matthay et al., 1999). Interestingly, CHD5
expression is usually maintained in spontaneously regressing
infant neuroblastomas (Garcia et al., 2010). Since regression
is also associated with differentiation, we speculate that the
retained ability to express CHD5 in these neuroblastomas
renders them responsive to RA-induced differentiation (Figures
6A; Figure S5A). It is possible that the 1p36 deletions render
cells incapable of differentiating, but these cells would also
need an additional oncogenic mutation to drive cellular
proliferation, such as MYCN amplification (Caron et al., 1993).
Indeed, 1p36 deletions are frequently accompanied by MYCN
amplifications (Brodeur, 2003). Furthermore, we observe
that upon Chd5 knockdown, progenitor cells retain several
undifferentiated characteristics but exhibit only a modestly
increased level of proliferation (Figures 2G and 2I). From a clin-
ical perspective, this implies that the status of CHD5 expres-
sion is a factor that one should take into account when
deciding whether or not to treat a neuroblastoma patient with
RA. In addition, strategies to reactivate CHD5 expression,
such as DNA demethylating agents, might prove useful for
increasing the effectiveness of RA in patients with epigenetic
silencing of one or two CHD5 alleles.
On a broader level, the deregulation of the H3K27me3 mark is
emerging as a common feature of cancer that appears to be
context dependent. For instance, EZH2 was recently reported
to have gain-of-function mutations in human B cell lymphomas
that correlate with elevated levels of H3K27me3 (Morin et al.,
2010; Yap et al., 2011). The H3K27me3 demethylase UTX is
frequently inactivated by a variety of deletions, truncations,
and frame-shift mutations in many different types of cancer
(van Haaften et al., 2009). EZH2 has also been reported to be
deleted and have inactivatingmutations in certainmyeloid leuke-
mias (Ernst et al., 2010; Nikoloski et al., 2010), and the histone H3
residue H3K27 is itself mutated in juvenile glioblastomas
(Schwartzentruber et al., 2012). Intriguingly, our results suggest
that deletion of CHD5 in neuroblastoma is another example of
H3K27me3 deregulation.
Further studies will be required to determine the functional
importance of the binding of CHD5 chromodomains to
H3K27me3 and whether this is essential for terminal differentia-
tion of neuronal progenitors. In summary, these results provide a
deeper understanding of the function of CHD5. Furthermore,
they suggest that the loss ofCHD5 contributes to neuroblastoma
via a defect in neuronal differentiation.
EXPERIMENTAL PROCEDURES
Peptide Pull-Down Assay
For peptide pull-down experiments, 1 mg of either unmodified or modified
biotinylated H3 peptides containing the amino acid sequence ARTKQTARK
STGGKAPRKQLATKAARKSAPATGGVKKPHR-YCK were first coupled to
streptavidin agarose beads (Invitrogen) in high salt (HS) buffer for 2 hr at 4C
(50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 0.1% (v/v) NP-40, 1 mMmental Cell 26, 223–236, August 12, 2013 ª2013 Elsevier Inc. 233
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in HS buffer, and cell or nuclear lysates were incubated with the beads for
an additional 2 hr. The beads were then washed four times with HS buffer,
and bound proteins were separated on SDS-PAGE gels in Laemmli buffer.
Preparation of Nuclear Protein Lysates
Cells were harvested, washed three times in PBS, and resuspended in ice-cold
nuclear extraction buffer (10 mM Tris-HCL (pH 8.0), 100 mM NaCl, 2 mM
MgCl2, 0.3M sucrose, 0.25% (v/v) NP40, 1 mg/ml aprotinin, 10 mg/ml leupeptin,
and 1 mM PMSF). The mixture was transferred to an ice-cold dounce for five
stokes with a tight-fitting pestle and then transferred to a 15ml tube and centri-
fuged at 4,000 rpm at 4C for 10 min. The supernatant was discarded and the
nuclear pellet was solubilized in HS buffer (50 mM Tris-HCl, pH 7.5, 300 mM
NaCl, 0.1% (v/v) NP-40, 1 mM PMSF), precleared by centrifugation at
14,000 rpm at 4C for 10 min, quantified, and used in either western blot or
peptide pull-down assays.
Western Blot Analysis
Cell pellets were lysed with HS buffer (300 mMNaCl, 50 mM Tris pH 7.2, 0.5%
Igepal CA630, 1 mM EDTA, pH 7.2), 10 mM leupeptin, 0.3 mM aprotinin, and
1 mM PMSF. Lysates were sonicated 2 3 10 s at 10% amplitude and cleared
by centrifugation at 20,000 3 g for 30 min at 4C. Laemmli sample buffer
(125 mM Tris-Cl [pH 6.8], 4% [w/v] SDS, 20% [v/v] glycerol, 0.02% [w/v]
bromophenol blue) and dithiothreitol (DTT) were added to the lysates (final
concentration of 100 mM) and an equal amount of protein was loaded onto
SDS-PAGE gels (BioRad). Subsequently, the proteins were transferred to a
Hybond-C extra membrane (Amersham) and blocked in 5% milk in PBS-T
(PBS with 0.1% Tween-20), followed by primary antibody incubation for
1–2 hr at room temperature. Anti-mouse or anti-rabbit horseradish peroxidase
(HRP)-coupled secondary antibody (Vector Laboratories) was added in
1:10,000 dilution and incubated for 1 hr. Supersignal West Pico (Thermo
Scientific) was used as chemical substrate.
Quantification of mRNA Levels by qPCR
Complementary DNA was generated by RT-PCR using the PE Applied Bio-
systems TaqMan reverse transcription reagents. Reactions were determined
using the SYBR Green I detection chemistry system (Applied Biosystems)
and an ABI Prism 7300 sequence detection system. RPO was used as a
control gene for normalization. The sequences of the primers used in this study
are available upon request.
Agilent Expression Analysis
Total RNA was extracted using the RNeasy Plus Mini Kit (QIAGEN). For each
treatment, RNA was prepared from three independent experiments and
pooled into one sample. Samples for microarray hybridization were synthe-
sized accordingly to the supplier’s instructions (Agilent). The 44K whole
mouse gene expression microarray, which interrogates all annotated tran-
scripts in the mouse genome, was used for gene expression profiling. For
each time point, two independent arrays were hybridized with pooled com-
plementary RNA. Hybridization, washing, staining, scanning, and data
analysis were performed according to the manufacturer’s instructions.
Expression levels were analyzed using the Genespring software program.
Tree-view diagrams were generated using the online resource Matrix2png
(Pavlidis and Noble, 2003). GO analysis was performed with FuncAssociate
2.0 (Berriz et al., 2009).
Surface Plasmon Resonance
K27me3 and H3 peptides from 500 nM stock solutions were injected in 1 min
pulses at 10 ml/min in HBS running buffer (10 mM HEPES, 150 mM NaCl,
0.005% Tween) onto individual streptavidin-coated flow cells of a series S
SA sensor chip until 1,000 RU peptide was immobilized on each flow cell,
with a blank flow cell used for reference subtraction on a BiaCore T200 instru-
ment. GST-CHD5-chromodomains was diluted in running buffer to working
concentrations of 2, 4, 8, and 16 nM. They were injected for 180 s to measure
the association constants, and the dissociation was followed for 300 s to mea-
sure the off rate. The KD was determined using a 1:1 Langmuir fit of these
sensorgrams.234 Developmental Cell 26, 223–236, August 12, 2013 ª2013 ElsevieIn Utero Knockdown of Chd5
Pregnant (E14) CD1 mice were anesthetized with isoflurane, the uterine
horns were exposed, and 1–1.5 ml of plasmid DNA (2–6 mg/ml) in PBS with
fast green (2 mg/ml; Sigma) was microinjected with glass microcapillaries
into the lateral ventricles of the embryos. Five electric pulses of 50 V for
50 ms were discharged at intervals of 950 ms across the head using an
electroporator (Nepagen CUY21D) and platinum electrodes (Nepagene
Cuy650P5). Embryos were retrieved at E18.5, and the brains were dissected
and fixed in 4% paraformaldehyde (PFA) overnight at 4C. After overnight
cryoprotection in 30% sucrose, the brains were cryosectioned onto Super-
frost Plus slides (Thermo Scientific).
Immunostaining
Cells and tissues were fixed in 4% PFA, blocked, and permeabilized in 5%
BSA in PBS-T (PBS with 0.2% Tween-20), followed by primary
antibody incubation in a cold room overnight using the following
antibodies: rabbit anti-CHD5 directed at the C or N terminus at 1:500
(see below); mouse anti-NEUN at 1:1,000 (Millipore); mouse anti-TUJ1 at
1:1,000 (Covance); goat anti-DCX at 1:500 (Santa Cruz Biotechnologies
[SCBT]); mouse anti-pH3 at 1:1,000 (Upstate Biotechnologies), guinea pig
anti-SOX3 at 1:1,000 (a kind gift from J. Muhr); rabbit anti-MAP2 1:1,000
(Millipore); rabbit anti-CHD3/4 1:200 (SCBT); mouse anti-PCNA at 1:400
(Oncogene); rabbit anti-CUX1 at 1:500 (SCBT); and mouse anti-S100b,
mouse anti-APC at 1:500, mouse anti-GFAP at 1:100, rat anti-BrdU at
1:250, mouse anti-TBR1 at 1:500, mouse anti-SATB2 at 1:100, and rabbit
anti-Ki67 at 1:500 (all from Abcam). Alexa Fluor-488, Alexa Fluor 555, and
Alexa Fluor 647 coupled secondary antibody (Life Technologies) was added
in 1:1,000 dilution and incubated for 1 hr. Images were taken with a LSM5
Exciter confocal microscope (Zeiss) and analyzed with Photoshop CS5
(Adobe).
ChIP, BioChIP, and High-Throughput Sequencing
ChIP assays were carried out as described previously with minor modifica-
tions (Bracken et al., 2006). Briefly, cells were crosslinked with ethylene
glycol bis(succinimidylsuccinate) for 45 min at room temperature, washed
with PBS, and further incubated with 1% formaldehyde for 10 min at room
temperature. Crosslinked chromatin was fragmented by sonication to an
average size of 200–350 bp and immunoprecipitated overnight with
1–10 mg of the indicated antibodies. For bioChIP, SH-SY5Y cells expressing
either FBio-Ctrl or FBio-CHD5 constructs (8 3 107 cells) were differentiated
in 10 mM of RA for 8 days. Sonicated chromatin was precleared with Protein
A beads and then incubated with 50 ml of streptavidin beads (Dynabeads
Streptavidin M280) at 4C overnight. Wash and elution steps were carried
out following the protocol described in Kim et al., (2009). ChIP DNA was
then quantified and used for library preparation using a standard ChIP-seq
sample preparation kit (Illumina). ChIP-seq library DNA was sequenced on
an Illumina HiSeq 2000 platform (BGI genomics). Base calling and mapping
of the 50 bp sequence reads to the human genome (hg19, February 2009
release) was performed using the burrows-wheeler alignment tool, allowing
for up to two mismatches in each read. Peak detection was performed using
MACS (Zhang et al., 2008) and the FBio-Ctrl data set served as a control for
normalization. Heatmaps were generated using the seqMINER algorithm (Ye
et al., 2011).
For further details regarding the materials and methods used in this work,
see the Supplemental Experimental Procedures.
ACCESSION NUMBERS
Data sets are available for download from NCBI’s Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo) through series accession number
GSE48314.
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